• Users Online: 14
  • Print this page
  • Email this page


 Coming soon

ORIGINAL ARTICLE
1.  Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer in Middle Eastern Population
2.  Pembrolizumab in advanced gastrointestinal malignancies with defective DNA mismatch repair: a case series
3.  THE IMPACT OF IMMUNE CHECKPOINT INHIBITOR-RELATED ADVERSE EVENTS AND THEIR IMMUNOSUPRESSIVE TREATMENT ON PATIENTSí OUTCOMES
CASE REPORT
1.  Inflammatory colitis after treatment of melanoma with talimogene laherparepvec (T-VEC)
2.  Bronchiolitis obliterans after combination immunotherapy with pembrolizumab and ipilimumab
REVIEW ARTICLE
1.  Pneumonitis after precision oncology therapies: A concise review
2.  Understanding the toxicity of cancer immunotherapies: Use of patient-reported outcomes